Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Boston Life Sciences identifies a second antiangiogenic molecule

Feb. 8, 1999

Orphan Medical's Busulfex Injection approved in U.S.

Feb. 8, 1999

Lorus Therapeutics announces preclinical data on anticancer compound

Feb. 8, 1999

Aronex's NDA for Atragen accepted for review

Feb. 5, 1999

Vitaxin proceeds to phase II

Feb. 5, 1999

First phase I clinical trials commence with NX-211

Feb. 4, 1999

Preclinical study of TRAIL points to promise as antitumor agent

Feb. 4, 1999

Ontogen completes phase I study of MDR-modulating compound

Feb. 3, 1999

First NDA filing for Prevatac expected to be delayed

Feb. 2, 1999

Ilex Oncology adds Canadian trial site to intoplicine development

Feb. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...